Lv2
180 积分 2025-08-17 加入
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
12天前
已完结
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
12天前
已完结
Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing
12天前
已完结
Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project
13天前
已完结
Prognostic Impact of ALK Rearrangements in Resected NSCLC: A Systematic Review and Meta-analysis
13天前
已完结
Management of Patients With Early-Stage Non-Small Cell Lung Cancer
13天前
已完结
Efficacy and safety of ensartinib in the treatment of non-small cell lung cancer: A systematic review of clinical trials
13天前
已完结
Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial
13天前
已完结
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer
13天前
已完结
Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non–small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors
14天前
已完结
皖公网安备34019202002308
